6 European Projects Found
Searched on 125080 European Projects
FINISHED
Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial (WAKE-UP)
Start date: Dec 1, 2011, End date: Nov 30, 2017,
WAKE-UP is an investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial designed to test efficacy and safety of MRI-based intravenous thrombolysis in patients with wake-up stroke. Every year 1.5 million patients suffer a stroke in the EU. Up to 20% of stroke patients wake up with stroke symptoms. Currently these patients are excluded from thrombolysis which is the onl ...
Read Project
13
Partners Participants
FINISHED
European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)
Start date: Jan 1, 2010, End date: Nov 30, 2016,
Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Read Project
34
Partners Participants
FINISHED
A quantitative model of thrombosis in intracranial aneurysms (THROMBUS)
Start date: Feb 1, 2011, End date: Apr 30, 2014,
Rupture risk of intracranial aneurysms (IA) has been studied at length. However, very little is known about the healing mechanism, namely the formation of a clot inside the cavity after insertion of a stent. The multiscale interaction between biological and hemodynamic processes is the central ingredient of this proposal. The core of the project is to develop and validate a biological model of spo ...
Read Project
10
Partners Participants
FINISHED
Clinical development of Enzyme Replacement Therapy in alpha-Mannosidosis patients using recombinant human enzyme (ALPHA-MAN)
Start date: Oct 1, 2010, End date: Mar 31, 2014,
Alpha-Mannosidosis is a rare Lysosomal Storage Disorder with a worldwide incidence of about 1:500 000. This orphan and devastating disease is caused by the deficiency of the lysosomal alpha-mannosidase (LAMAN) which is responsible for the intralysosomal degradation of mannosyl linked oligosaccharides. To date no causative treatment for alpha-Mannosidosis is available and since most of the children ...
Read Project
12
Partners Participants
FINISHED
Development of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children (LOULLA&PHILLA)
Start date: Nov 1, 2008, End date: Apr 30, 2012,
"Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium. This Consortium is composed of highly qualified organizations and notorious clinicians in pediatric hemato-oncology. The Consortium is an integrated team of competencies (clinicians, pædiatric ...
Read Project
12
Partners Participants
FINISHED
Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (Mitotarget)
Start date: Feb 1, 2009, End date: Mar 31, 2012,
Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Read Project
